| Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript |
Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Georgia Erbez - Chief Financial Officer Stefan Lutz - Senior Vice President of Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Tycho Peterson - Jefferies Allison Bratzel - Piper Sandler Dan Arias - Stifel Matthew Hewitt - Craig-Hallum Brendan Smith - TD Cowen Operator Greetings and welcome to the Codexis First Quarter 2025 Earnings Conference Call and webcast. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2025-05-14 22:50:32 |
Czytaj oryginał (ang.) |
| Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates |
Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago. |
zacks.com |
2025-05-14 22:40:41 |
Czytaj oryginał (ang.) |
| Codexis Reports First Quarter 2025 Financial Results |
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. |
globenewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting |
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Codexis to Report First Quarter 2025 Financial Results on May 14 |
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. |
globenewswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy? |
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:09:20 |
Czytaj oryginał (ang.) |
| Codexis Announces Byron Dorgan to Retire from Board of Directors |
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company's Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board. |
globenewswire.com |
2025-04-09 21:00:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan. |
globenewswire.com |
2025-03-07 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript |
Codexis, Inc. (NASDAQ:CDXS ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Georgia Erbez - Chief Financial Officer Conference Call Participants Richard Miller - Cantor Fitzgerald, L.P. Matthew Stanton - Jefferies Group LLC Allison Bratzel - Piper Sandler Companies Dan Arias - Stifel Financial Corp. Jacob Johnson - Stephens Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC Brendan Smith - TD Cowen Operator Welcome to the Codexis Fourth Quarter and Full Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-28 00:20:02 |
Czytaj oryginał (ang.) |
| Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates |
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.02 per share a year ago. |
zacks.com |
2025-02-27 21:35:20 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 39,000 shares of Codexis common stock and (ii) 27,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan. |
globenewswire.com |
2025-02-14 19:15:00 |
Czytaj oryginał (ang.) |
| Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th |
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. |
globenewswire.com |
2025-02-13 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board |
REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Arthur Levin, PhD, to the Company's Strategic Advisory Board (SAB). Dr. Levin is a founding member of Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called antibody oligonucleotide conjugates, and currently serves on its Board of Directors. He brings three decades of experience developing oligonucleotides to Codexis as it continues to onboard customers for its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis™ manufacturing platform. |
globenewswire.com |
2025-02-06 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Appoints Christos Richards to Board of Directors |
REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Christos Richards to the Company's Board of Directors. |
globenewswire.com |
2025-01-16 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 23,000 shares of Codexis common stock and (ii) 11,500 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan. |
globenewswire.com |
2025-01-10 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 168,400 shares of Codexis common stock and (ii) 39,750 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. |
globenewswire.com |
2024-12-06 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference |
REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Piper Sandler 36th Annual Healthcare Conference, being held December 3-5, 2024, in New York, New York. |
globenewswire.com |
2024-11-19 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics |
—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes— —Management to host conference call today at 4:30 pm EST to discuss data— REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. |
globenewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors |
REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Raymond De Vré, PhD, to the Company's Board of Directors. |
globenewswire.com |
2024-11-12 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics |
—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type enzymes— —Management to host conference call on Thursday, November 14 to discuss data— REDWOOD CITY, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will demonstrate real-world application of its enzymatic synthesis platform via three presentations at the upcoming TIDES Europe annual meeting, being held November 12-14, 2024, in Hamburg, Germany. |
globenewswire.com |
2024-11-11 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of an equity grant to one new employee as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employee received an equity award consisting of (i) options to purchase 50,000 shares of Codexis common stock and (ii) 15,000 restricted stock units (RSUs) as an inducement award under the company's 2024 Inducement Plan. |
globenewswire.com |
2024-11-08 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis to Participate in Upcoming Healthcare Conferences |
REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences. |
globenewswire.com |
2024-11-04 18:05:00 |
Czytaj oryginał (ang.) |
| Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript |
Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-01 00:48:09 |
Czytaj oryginał (ang.) |
| Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates |
Codexis (CDXS) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.26 per share a year ago. |
zacks.com |
2024-10-31 20:31:25 |
Czytaj oryginał (ang.) |
| Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting |
Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform |
globenewswire.com |
2024-10-24 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to eight new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 350,175 shares of Codexis common stock and (ii) 80,138 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. Included in this total are equity awards for Codexis' newly appointed Chief Financial Officer, Georgia Erbez. As part of her inducement to commence employment, Ms. Erbez was granted an option to purchase 300,000 shares of Company common stock and 50,000 shares of RSUs. |
globenewswire.com |
2024-10-14 11:05:00 |
Czytaj oryginał (ang.) |
| Codexis to Report Third Quarter 2024 Financial Results on October 31 |
REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the third quarter of 2024 on Thursday, October 31, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update. |
globenewswire.com |
2024-10-10 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company |
Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of growth REDWOOD CITY, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an increase in its cash reserves through capital raises totaling $31 million via the Company's existing at-the-market facility during the quarter ended September 30, 2024. |
globenewswire.com |
2024-10-02 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences |
Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications |
globenewswire.com |
2024-10-01 11:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. |
globenewswire.com |
2024-09-06 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis to Participate in Upcoming Healthcare Conferences |
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences. |
globenewswire.com |
2024-09-03 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting |
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel discussion at the upcoming RNA Leaders annual meeting, being held September 4-5, 2024, in San Diego, CA. The Company's presentations will focus on the use of enzymes to drive the scalable and cost-effective manufacture of short inhibitory ribonucleic acid (siRNA) duplexes. |
globenewswire.com |
2024-08-20 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis Announces New Employment Inducement Grants |
REDWOOD CITY, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 137,950 shares of Codexis common stock and (ii) 27,000 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan. |
globenewswire.com |
2024-08-16 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis Publishes FY2023 Sustainability Disclosures |
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board |
globenewswire.com |
2024-08-15 20:05:00 |
Czytaj oryginał (ang.) |
| Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript |
Codexis, Inc. (NASDAQ:CDXS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research Kevin Norrett - COO Sri Ryali - CFO Conference Call Participants Matt Stanton - Jefferies Operator Welcome to the Codexis Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-08-09 03:01:11 |
Czytaj oryginał (ang.) |